Contraindicated (1)bortezomib will improve the amount or outcome of mavacamten by influencing hepatic enzyme CYP2C19 metabolism. Contraindicated. Powerful or reasonable CYP2C19 inhibitors may well enhance mavacamten systemic publicity, leading to coronary heart failure as a consequence of systolic dysfunction. levoketoconazole will boost the stage or outcome of bortezomib by affecting https://ewarta221nyi4.idblogmaker.com/profile